If the disease causing microorganism ecological system was a battlefield, Nuvilex (OTCQB: NVLX) would be dubbed an assassin. The upcoming biotech player, renowned for its peerless innovation, is going after the ‘untouchables’. It’s Cell in a box technology seems to be the driving force behind innumerable breakthroughs in the fight against notorious health adversities like cancer and diabetes.
Reasonable advancements in fighting pancreatic cancer
Pancreatic cancer has and will continue being in the crosshairs of biotech experts. Despite continuous efforts, many biotech players have recorded zero progress in the fight against this vile condition. Nuvilex has however managed to spearhead some reasonable breakthroughs.
I would love to save you all the medical jargon and put it in simple terms.
Through high-end proprietary technology and methods, Nuvilex has been able to come up with a safe and effective way of killing pancreatic cancer cells. This has been principally achieved through the help of the all too famous Cell-in-a-Box technology.
As an investor what does this mean? It means growth! Companies that exhibit a tendency to spearhead breakthroughs have been known to grow exponentially. It is one of those unwritten tendencies that have proved their relevance through continued observation. This therefore means that Nuvilex extends the opportunity to grow.
Cell-In-a-Box Encapsulation technology- What’s the ruckus about?
Anyone familiar with Nuvilex is at the top of their voice with this so called encapsulation technology. I believe that it is obligatory for investors to get a clear understanding of the idea. This way, investors will not be misled by the critic incline which in recent days seems to be border on satirical lines. It isn’t uncommon to find critics who know very little of a subject matter lashing out in profound satirical tones.
Back to the matter at hand, Encapsulation technology; what is it? Better yet, how does it operate and what prospects does it unearth for Nuvilex? Cell encapsulation in general is primarily geared towards snuffing out the prevailing problem of graft rejection. Nuvilex now takes cell encapsulation technology to a whole new different orientation through its Cell-in-a-Box technology.
Basically, Cell-in-a-Box technology steers the implementation of cell encapsulation. It allows for the encapsulated cell to be frozen and stored. In actual fact, it allows implanting to be prolonged. This avails multiple benefits and acts like a delay timer. Scientists get the opportunity to examine the patient more intensively without the worry of compromise in stem cell viability. Nonetheless, the most outstanding reason meriting my strong advocacy for Cell-in-a- Box technology and cell encapsulation is the fact that is exclamatory on safety. Unlike direct injection, encapsulated cells remain isolated in the target area after encapsulation. This suffocates the likeliness of side effects.
As a conclusion, I would say that Nuvilex (NVLX) is doing a great job with regard to its operations. Its only drawback is that mainstream competitors enjoy economies of scale.
As an investor, you have to ask yourself the question, where is the company going from here? I believe that this concise sneak peek into Nuvilex answer gives a positive and candid answer.I am still bullish on Nuvilex (NVLX)- a definite buy.